

巻頭カラー

p.6 Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. *J Hepatol.* 2018;69(4):896-904.

p.6 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology.* 2018;67(1):328-57.

p.6,7 Nagaya T, Tanaka N, Suzuki T, Sano K, Horiuchi A, Komatsu M, et al. Down-regulation of SREBP-1c is associated with the development of burned-out NASH. *J Hepatol.* 2010;53(4):724-31.

p.11 Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. *International journal of obesity (2005).* 2008;32(4):619-28.

p.12 Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. *Nature reviews Endocrinology.* 2017;13(9):509-20.

p.13 Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. *Nature reviews Endocrinology.* 2017;13(10):572-87.

p.14 Kadowaki S, Tamura Y, Someya Y, Takeno K, Kaga H, Sugimoto D, et al. Fatty Liver Has Stronger Association With Insulin Resistance Than Visceral Fat Accumulation in Nonobese Japanese Men. *Journal of the Endocrine Society.* 2019;3(7):1409-16.

p.15 Hashikura Y, Ichida T, Umeshita K, Kawasaki S, Mizokami M, Mochida S, et al. Donor complications associated with living donor liver transplantation in Japan. *Transplantation.* 2009;88(1):110-4.

p.15 Makuuchi M. Living donor liver transplantation: looking back at my 30 years of experience. *Surgery today.* 2019;49(4):288-94.

第1章

p.42 Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology.* 2010;51(1):121-9.

p.42 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. *Gastroenterology.* 2015;149(2):367-78.e5; quiz e14-5.

p.46 Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. *International journal of obesity (2005).* 2008;32(4):619-28.

- p.49** Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet*. 2018;391(10120):541-51.
- p.51** Wansink B, Chandon P. Meal size, not body size, explains errors in estimating the calorie content of meals. *Annals of internal medicine*. 2006;145(5):326-32.
- p.54** An R. Beverage Consumption in Relation to Discretionary Food Intake and Diet Quality among US Adults, 2003 to 2012. *Journal of the Academy of Nutrition and Dietetics*. 2016;116(1):28-37.
- p.54** Yamada M, Murakami K, Sasaki S, Takahashi Y, Okubo H. Soft drink intake is associated with diet quality even among young Japanese women with low soft drink intake. *Journal of the American Dietetic Association*. 2008;108(12):1997-2004.
- p.54** Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. *Nature*. 2014;514(7521):181-6.
- p.58** 西森 栄, 尾形 哲, 高杉 一, 依田 と, 大井 さ, 関口 憲, et al. 糖質制限食は2型糖尿病に伴う非アルコール性脂肪性肝疾患をカロリー制限食と同等に改善させる. *糖尿病*. 2018;61(5):297-306.
- p.60** Maeda H, Katsuki T, Akaike T, Yasutake R. High correlation between lipid peroxide radical and tumor-promoter effect: suppression of tumor promotion in the Epstein-Barr virus/B-lymphocyte system and scavenging of alkyl peroxide radicals by various vegetable extracts. *Japanese journal of cancer research : Gann*. 1992;83(9):923-8.
- p.62** Bouvard V, Loomis D, Guyton KZ, Grosse Y, Ghissassi FE, Benbrahim-Tallaa L, et al. Carcinogenicity of consumption of red and processed meat. *The Lancet Oncology*. 2015;16(16):1599-600.
- p.63** Godos J, Micek A, Brzostek T, Toledo E, Iacoviello L, Astrup A, et al. Egg consumption and cardiovascular risk: a dose-response meta-analysis of prospective cohort studies. *European journal of nutrition*. 2021;60(4):1833-62.
- p.66** Elizabeth L, Machado P, Zinöcker M, Baker P, Lawrence M. Ultra-Processed Foods and Health Outcomes: A Narrative Review. *Nutrients*. 2020;12(7).
- p.67** Hall KD, Ayuketah A, Brychta R, Cai H, Cassimatis T, Chen KY, et al. Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. *Cell metabolism*. 2019;30(1):67-77.e3.
- p.69** Iwayama K, Kurihara R, Nabekura Y, Kawabuchi R, Park I, Kobayashi M, et al. Exercise Increases 24-h Fat Oxidation Only When It Is Performed Before Breakfast. *EBioMedicine*. 2015;2(12):2003-9.
- p.76** Nemoto K, Gen-no H, Masuki S, Okazaki K, Nose H. Effects of high-intensity interval walking training on physical fitness and blood pressure in middle-aged and older people. *Mayo Clin Proc*. 2007;82(7):803-11.

第 2 章

- p.91** Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. *Nature reviews Endocrinology*. 2017;13(10):572-87.
- p.99** Huang Y, Lu Y, Huang YM, Wang M, Ling W, Sui Y, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. *Metabolism: clinical and experimental*. 2020;113:154378.
- p.100** Joint FAOWHOUNUECoE, Protein R, Food, Agriculture Organization of the United N, World Health O, United Nations U. Energy and protein requirements : report of a Joint FAO/WHO/UNU Expert Consultation [held in Rome from 5 to 17 October 1981]. Geneva: World Health Organization; 1985.
- p.104** Nagaya T, Tanaka N, Suzuki T, Sano K, Horiuchi A, Komatsu M, et al. Down-regulation of SREBP-1c is associated with the development of burned-out NASH. *J Hepatol*. 2010;53(4):724-31.
- p.105** Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. *J Hepatol*. 2018;69(4):896-904.
- P106** Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2018;67(1):328-57.
- p.106** Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. *JHEP reports : innovation in hepatology*. 2020;2(6):100192.
- p.108** Machado MV, Diehl AM. Pathogenesis of Nonalcoholic Steatohepatitis. *Gastroenterology*. 2016;150(8):1769-77.
- p.111** Jang C, Hui S, Lu W, Cowan AJ, Morscher RJ, Lee G, et al. The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. *Cell metabolism*. 2018;27(2):351-61.e3.
- p.112** Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. *J Hepatol*. 2018;69(4):896-904.
- p.113** Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2015;149(2):389-97.e10.
- p.113** Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc*. 1980;55(7):434-8.
- p.114** Hashikura Y, Makuuchi M, Kawasaki S, Matsunami H, Ikegami T, Nakazawa Y, et al. Successful living-related partial liver transplantation to an adult patient. *Lancet*. 1994;343(8907):1233-4.

- p.115 Hashikura Y, Ichida T, Umeshita K, Kawasaki S, Mizokami M, Mochida S, et al. Donor complications associated with living donor liver transplantation in Japan. *Transplantation*. 2009;88(1):110-4.
- p.116 日本肝移植学会. 肝移植症例登録報告. *移植*. 2021;56(3):217-33.
- p.118 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology*. 2010;52(5):1836-46.
- p.127 岡上 武, 水野 雅. 肝機能検査、肝障害について一健診における問題点. *総合健診*. 2015;42(2):307-12.
- p.128 Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2015;149(2):389-97.e10.
- p.129 Ishiba H, Sumida Y, Tanaka S, Yoneda M, Hyogo H, Ono M, et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. *J Gastroenterol*. 2018;53(11):1216-24.
- p.129 Selvaraj EA, Mózes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. *J Hepatol*. 2021;75(4):770-85.
- p.130 Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, et al. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. *International journal of molecular sciences*. 2020;21(6).
- p.131 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. *Nat Med*. 2018;24(7):908-22.
- p.134 伊藤裕. メタボリックドミノとは-生活習慣病の新しいとらえ方. *日本臨牀*. 2003;61:1842-3.
- p.134 伊藤 裕. 14) メタボリックドミノと先制医療. *日本内科学会雑誌*. 2018;107(9):1913-20.

第3章

- p.140 Nanri A, Mizoue T, Noda M, Takahashi Y, Kato M, Inoue M, et al. Rice intake and type 2 diabetes in Japanese men and women: the Japan Public Health Center-based Prospective Study. *The American journal of clinical nutrition*. 2010;92(6):1468-77.
- p.140 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology*. 2010;52(5):1836-46.
- p.140 Hu EA, Pan A, Malik V, Sun Q. White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review. *BMJ (Clinical research ed)*. 2012;344:e1454.
- p.150 Jensen T, Abdelmalek MF, Sullivan S, Nadeau KJ, Green M, Roncal C, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. *J Hepatol*. 2018;68(5):1063-75.

- p.154** WHO Guidelines Approved by the Guidelines Review Committee. Guideline: Sugars Intake for Adults and Children. Geneva: World Health Organization
Copyright © World Health Organization, 2015.; 2015.
- p.154** Powell LM, Chriqui JF, Khan T, Wada R, Chaloupka FJ. Assessing the potential effectiveness of food and beverage taxes and subsidies for improving public health: a systematic review of prices, demand and body weight outcomes. *Obesity reviews : an official journal of the International Association for the Study of Obesity.* 2013;14(2):110-28.
- p.155** シンガポール保健省 <https://hpb.gov.sg/healthy-living/food-beverage/nutri-grade>、
Neelakantan N, Park SH, Chen GC, van Dam RM. Sugar-sweetened beverage consumption, weight gain, and risk of type 2 diabetes and cardiovascular diseases in Asia: a systematic review. *Nutrition reviews.* 2021;80(1):50-67.
- p.161** Jang C, Wada S, Yang S, Gosis B, Zeng X, Zhang Z, et al. The small intestine shields the liver from fructose-induced steatosis. *Nature metabolism.* 2020;2(7):586-93.
- p.167** O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. *Hepatology.* 2010;51(1):307-28.
- p.168** Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. *Gastroenterology.* 2011;141(5):1572-85.
- p.176** Egawa H, Ueda Y, Kawagishi N, Yagi T, Kimura H, Ichida T. Significance of pretransplant abstinence on harmful alcohol relapse after liver transplantation for alcoholic cirrhosis in Japan. *Hepatol Res.* 2014;44(14):E428-36.
- p.177** Higuchi S, Matsushita S, Muramatsu T, Murayama M, Hayashida M. Alcohol and aldehyde dehydrogenase genotypes and drinking behavior in Japanese. *Alcoholism, clinical and experimental research.* 1996;20(3):493-7.
- p.178** 尾崎米厚, 文 金. アルコールの疫学—わが国の飲酒行動の実態とアルコール関連問題による社会的損失のインパクト. *医学のあゆみ.* 2020;274(1):34-9.
- p.182** Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. *Annals of internal medicine.* 2002;137(12):947-54.
- p.183** 恩地 森, 滝川 一, 村田 洋, 小島 裕, 橋本 直, 久持 顕, et al. 民間薬および健康食品による薬物性肝障害の調査. *肝臓.* 2005;46(3):142-8.
- p.185** 滝川 一. 薬物性肝障害の診断と治療. *日本内科学会雑誌.* 2015;104(5):991-7.
- p.187** Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. *Am J Gastroenterol.* 2021;116(5):878-98.
- p.188** Yoshimura N. [Epidemiology of bone and joint disease - the present and future - . Epidemiology of lumbar spondylosis in Japan : the ROAD study]. *Clinical calcium.* 2014;24(5):665-8.
- p.192** Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of

metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. *Schizophrenia bulletin*. 2013;39(2):306-18.

p.196 Field TS, Gurwitz JH, Avorn J, McCormick D, Jain S, Eckler M, et al. Risk factors for adverse drug events among nursing home residents. *Archives of internal medicine*. 2001;161(13):1629-34.

p.197 Stoehr GP, Lu SY, Lavery L, Bilt JV, Saxton JA, Chang CC, et al. Factors associated with adherence to medication regimens in older primary care patients: the Steel Valley Seniors Survey. *The American journal of geriatric pharmacotherapy*. 2008;6(5):255-63.

p.198 金子 一. 経口補水療法--わが国における現状と今後の展望 (ミニ特集 小児の輸液療法). *小児科臨床*. 2008;61(1):13-23.

第4章

p.208 日本消化器病学会関連研究会慢性便秘の診断・治療研究会, 日本消化器病学会. 慢性便秘症診療ガイドライン: 南江堂; 2017. xv, 95p p.

p.208 Bharucha AE, Lacy BE. Mechanisms, Evaluation, and Management of Chronic Constipation. *Gastroenterology*. 2020;158(5):1232-49.e3.

p.209 Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*. 2006;444(7122):1027-31.

p.216 西森 栄, 尾形 哲, 高杉 一, 依田 と, 大井 さ, 関口 憲, et al. 糖質制限食は2型糖尿病に伴う非アルコール性脂肪性肝疾患をカロリー制限食と同等に改善させる. *糖尿病*. 2018;61(5):297-306.

p.221 Bharucha AE, Lacy BE. Mechanisms, Evaluation, and Management of Chronic Constipation. *Gastroenterology*. 2020;158(5):1232-49.e3.

p.224 Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, et al. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. *International journal of molecular sciences*. 2021;22(15).

p.225 Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, et al. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. *The lancet Gastroenterology & hepatology*. 2020;5(11):996-1007.

第5章

p.236 Ito T, Ishigami M, Zou B, Tanaka T, Takahashi H, Kurosaki M, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. *Hepatology international*. 2021;15(2):366-79.

p.236 Lee YH, Kim SU, Song K, Park JY, Kim DY, Ahn SH, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). *Hepatology*. 2016;63(3):776-

86.

p.236 Shida T, Oshida N, Suzuki H, Okada K, Watahiki T, Oh S, et al. Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan. *Hepatol Res.* 2020;50(9):1032-46.

p.237 Kawaguchi T, Shima T, Mizuno M, Mitsumoto Y, Umemura A, Kanbara Y, et al. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. *PLoS One.* 2018;13(1):e0185490.

p.238 Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. *J Hepatol.* 2017;66(1):142-52.

p.240 Martens EA, Lemmens SG, Westerterp-Plantenga MS. Protein leverage affects energy intake of high-protein diets in humans. *The American journal of clinical nutrition.* 2013;97(1):86-93.

p.241 Gosby AK, Conigrave AD, Lau NS, Iglesias MA, Hall RM, Jebb SA, et al. Testing protein leverage in lean humans: a randomised controlled experimental study. *PLoS One.* 2011;6(10):e25929.

p.242 Gosby AK, Conigrave AD, Raubenheimer D, Simpson SJ. Protein leverage and energy intake. *Obesity reviews : an official journal of the International Association for the Study of Obesity.* 2014;15(3):183-91